Adrixetinib

Adrixetinib (Q702) 是一种具有口服活性的 CSF1R、Mer 和 Axl 三重抑制剂,其 Kd 值分别为 8.7 nM、0.8 nM 和 0.3 nM,作为一种强效免疫调节剂,它可重塑肿瘤微环境,增加 M1 巨噬细胞和 CD8+ T 细胞的丰度,同时降低 M2 巨噬细胞和髓源性抑制细胞 (MDSCs) 的水平,并上调肿瘤细胞中 MHC I 类分子 (MHC class I) 和 E-钙粘蛋白 (E-cadherin) 的表达,在同源小鼠肿瘤模型中表现出显著的抗肿瘤功效,适用于乳腺癌、肾腺癌、结肠癌和黑色素瘤的研究。
产品编号: MS-O37598 纯度: 99.55% CAS No.: 2394874-66-7 分子式: C25H24F3N5O5 分子量: 531.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Adrixetinib (Q702) 是一种具有口服活性的 CSF1R、Mer 和 Axl 三重抑制剂,其 Kd 值分别为 8.7 nM、0.8 nM 和 0.3 nM,作为一种强效免疫调节剂,它可重塑肿瘤微环境,增加 M1 巨噬细胞和 CD8+ T 细胞的丰度,同时降低 M2 巨噬细胞和髓源性抑制细胞 (MDSCs) 的水平,并上调肿瘤细胞中 MHC I 类分子 (MHC class I) 和 E-钙粘蛋白 (E-cadherin) 的表达,在同源小鼠肿瘤模型中表现出显著的抗肿瘤功效,适用于乳腺癌、肾腺癌、结肠癌和黑色素瘤的研究。

生物实验数据

生物活性 Adrixetinib (Q702) is an orally active triple inhibitor of CSF1R, Mer, and Axl with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively, and as a potent immunomodulator it remodels the tumor microenvironment by increasing the abundance of M1 macrophages and CD8+ T cells while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs), upregulates the expression of MHC class I and E-cadherin in tumor cells, exhibits significant antitumor efficacy in syngeneic mouse tumor models, and is applicable for research on breast cancer, renal adenocarcinoma, colon cancer, and melanoma.
IC50 & Target Axl:0.3 nM (Kd), Mer:0.8 nM (Kd)
体外研究
(In Vitro)

Adrixetinib (Q702) (孵育 1 小时) 可强效结合并抑制纯化的 Axl、Mer 和 CSF1R 激酶,其 IC50 值分别为 0.3 nM、0.8 nM 和 8.7 nM。
Adrixetinib (0.001-10 μM; 24 h pretreatment) 可浓度依赖性地抑制 H1299 细胞中 Gas6 诱导的 Axl 和 AKT 磷酸化,浓度依赖性地抑制 A549 细胞中 Gas6 诱导的 Mer 和 AKT 磷酸化,还可浓度依赖性地抑制 THP-1 细胞中 CSF1 诱导的 CSF1R 和 ERK 磷酸化。
Adrixetinib (0.1-100 μM; 72 h) 可直接抑制 EMT6 细胞活力,其 IC50 为 8.4 μM。
Adrixetinib 通过 CSF1R 通路抑制 M-NFS-60 细胞增殖,IC50 < 1.0 μM,表现出强大的细胞活性。

Western Blot Analysis

Cell Line: H1299 cells
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: 24 h (pretreatment); 1 h (Gas6 stimulation)
Result: Inhibited Gas6-induced phosphorylation of Axl (Tyr702) and AKT (Ser473) in a concentration-dependent manner.

Western Blot Analysis

Cell Line: A549 cells
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: pretreatment; 1 h (Gas6 stimulation)
Result: Inhibited Gas6-induced phosphorylation of Mer (Tyr749/Tyr753/Tyr754) and AKT (Ser473) in a concentration-dependent manner.

Western Blot Analysis

Cell Line: THP-1 cells
Concentration: 0.001, 0.01, 0.1, 1, 10 μM
Incubation Time: 24 h (pretreatment); 5 min (CSF1 stimulation)
Result: Inhibited CSF1-induced phosphorylation of CSF1R (Tyr723) and ERK (Thr202/Tyr204) in a concentration-dependent manner.

Cell Viability Assay

Cell Line: EMT6 mouse triple-negative breast cancer cells
Concentration: 0.1, 1, 10, 100 μM
Incubation Time: 72 h
Result: Exhibited direct cytotoxicity against EMT6 cells with an IC50 of 8.4 μM.
体内研究
(In Vivo)

Adrixetinib (Q702) (30 mg/kg;口服;每日一次;连续 7 天) 可抑制裸鼠皮下异种移植瘤中 Axl 和 CSF1R 的磷酸化。
Adrixetinib (10-100 mg/kg;口服;每日一次;连续 14 天) 可在 BALB/c 小鼠的皮下 EMT6 同源乳腺癌肿瘤中诱导剂量依赖性的肿瘤生长抑制 (抑制率为 54.3%至 84.6%)。
Adrixetinib (30 mg/kg;口服;每日给药;最长 7 天) 可调控皮下 EMT6 肿瘤中的 EMT6 基因表达,从而在 BALB/c 小鼠中促进免疫刺激微环境的形成。
Adrixetinib (30 mg/kg;口服;每日一次;第 5 至 22 天) 可重塑皮下移植瘤中免疫细胞群,并调控 BALB/c 小鼠的 MHC-I 及 E-钙粘蛋白表达。
Adrixetinib (30 mg/kg;口服;每日一次;连续 7 天) 可通过在 BALB/c 小鼠的皮下 EMT6 肿瘤组织及外周血中提升 IFN-γ 与颗粒酶 B 的产生,增强 T 细胞和自然杀伤细胞的效应功能。
Adrixetinib (30 mg/kg;口服;每日 1 次;连续 21 天) 可增加 BALB/c 小鼠皮下 EMT6 肿瘤中 CD8 T 细胞的浸润,减少髓系细胞的聚集,并上调 MHC-I 和 PD-L1 的表达。
Adrixetinib (30 mg/kg;口服;每日 1 次;连续 9 天) 可增加 C57BL/6 小鼠皮下 B16F10-OVA 黑色素瘤肿瘤中肿瘤抗原特异性 CD8 T 细胞的浸润。
Adrixetinib (30 mg/kg;口服;每日;最长 27 天) 可在小鼠皮下 CT26、MC38 和 RENCA 同源肿瘤模型中诱导肿瘤生长抑制 (64% 至 77% TGI)。

Animal Model: BALB/c nude (female, 6-8 weeks old, subcutaneously implanted with H1299 human non-small cell lung carcinoma cells or M-NFS-60 murine myeloid leukemia cells mixed with Matrigel)
Dosage: 30 mg/kg
Administration: p.o.; daily; 7 days
Result: Inhibited phosphorylation of Axl in H1299 tumor samples.
Inhibited phosphorylation of CSF1R in M-NFS-60 tumor samples.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)
Dosage: 10 mg/kg; 30 mg/kg; 100 mg/kg
Administration: p.o.; daily; 14 days
Result: Achieved 54.3%, 64.9%, and 84.6% tumor growth control, respectively, and significantly reduces tumor volume compared with the control group.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)
Dosage: 30 mg/kg
Administration: p.o.; daily; up to 7 days
Result: Upregulated CD8⁺ T cell, natural killer cell and MHC‑I signature genes in a time‑dependent manner.
Downregulated tumor‑associated macrophage and myeloid‑derived suppressor cell signature genes in a time‑dependent manner.
Validated enhanced immune‑activating signatures and diminished immunosuppressive signatures by day 7 using gene expression heatmaps.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)
Dosage: 30 mg/kg
Administration: p.o.; daily; 5 or 22 days
Result: Reduced tumor volume significantly compared with controls by day 22.
Decreased the proportion of tumor-infiltrating M-MDSCs by 2.3-fold and repolarized tumor-associated macrophages toward the M1 phenotype while reducing M2 populations, with these immune alterations sustained through day 22.
Elevated CD8⁺ T cell proportions at both days 5 and 22, and preserved higher MHC-I and increased E-cadherin protein expression in tumors by day 22.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)
Dosage: 30 mg/kg
Administration: p.o.; daily; 7 days
Result: Significantly increased proportion of IFN-γ-producing CD4 T cells and granzyme B+ CD8 T cells in tumor samples relative to controls.
Significantly increased proportion of IFN-γ-producing CD4 T and natural killer cells, and granzyme B+ CD8 T cells in peripheral blood relative to controls.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with EMT6 murine triple-negative breast carcinoma cells)
Dosage: 30 mg/kg
Administration: p.o.; daily; 21 days
Result: Increased tumor-infiltrating CD8 T cell percentages relative to controls.
Decreased myeloid cell percentages relative to controls.
Increased MHC-I and PD-L1 protein expression in CD45-negative tumor cells relative to controls.
Animal Model: C57BL/6 (female, 7-8 weeks old, subcutaneously implanted with B16F10-OVA murine melanoma cells)
Dosage: 30 mg/kg
Administration: p.o.; daily; 9 days
Result: Induced partial tumor growth inhibition.
Significantly increased percentage of OVA-specific CD8 T cells (detected via SIINFEKL-H-2Kb tetramer staining) in tumor samples relative to controls.
Animal Model: BALB/c (female, 6-8 weeks old, subcutaneously implanted with RENCA murine renal adenocarcinoma cells or CT26 murine colon carcinoma cells); C57BL/6 (female, 6-8 weeks old, subcutaneously implanted with MC38 murine colon adenocarcinoma cells)
Dosage: 30 mg/kg
Administration: p.o.; daily; up to 27 days
Result: Achieved 77% tumor growth control in CT26 colon tumors by day 27.
Achieved 64% tumor growth control in MC38 colon tumors by day 27.
Reduced tumor volume in RENCA renal tumors relative to controls.
性状 固体
颜色 White to off-white

化学信息

分子量 531.48
分子式 C25H24F3N5O5
CAS No. 2394874-66-7
别名 Q702

储存&溶解度

储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (188.15 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8815 mL9.4077 mL18.8154 mL47.0385 mL
5 mM0.3763 mL1.8815 mL3.7631 mL9.4077 mL
10 mM0.1882 mL0.9408 mL1.8815 mL4.7038 mL
15 mM0.1254 mL0.6272 mL1.2544 mL3.1359 mL
20 mM0.0941 mL0.4704 mL0.9408 mL2.3519 mL
25 mM0.0753 mL0.3763 mL0.7526 mL1.8815 mL
30 mM0.0627 mL0.3136 mL0.6272 mL1.5679 mL
40 mM0.0470 mL0.2352 mL0.4704 mL1.1760 mL
50 mM0.0376 mL0.1882 mL0.3763 mL0.9408 mL
60 mM0.0314 mL0.1568 mL0.3136 mL0.7840 mL
80 mM0.0235 mL0.1176 mL0.2352 mL0.5880 mL
100 mM0.0188 mL0.0941 mL0.1882 mL0.4704 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础